Home  »  Finance   »  Analysts Predict An VYNE Therapeutics Inc. (NASDAQ...

Analysts Predict An VYNE Therapeutics Inc. (NASDAQ: VYNE) Spike?

VYNE Therapeutics Inc. (NASDAQ:VYNE) shares, rose in value on Friday, 05/13/22, with the stock price up by 7.25% to the previous day’s close as strong demand from buyers drove the stock to $0.40.

Actively observing the price movement in the last trading, the stock closed the session at $0.37, falling within a range of $0.3676 and $0.4199. Referring to stock’s 52-week performance, its high was $4.24, and the low was $0.34. On the whole, VYNE has fluctuated by -29.55% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.

Sponsored

With the market capitalization of VYNE Therapeutics Inc. currently standing at about $22.87 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 02, 2022 – Mar 07, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.24, which is expected to increase to -$0.15 for fiscal year -$1.36 and then to about -$0.78 by fiscal year 2022. Data indicates that the EPS growth is expected to be 82.70% in 2022, while the next year’s EPS growth is forecast to be 42.60%.

Analysts have estimated the company’s revenue for the quarter at $4.12 million, with a low estimate of $3.9 million and a high estimate of $4.4 million. According to the average forecast, sales growth in current quarter could jump down -3.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $16.57 million, representing a decrease of -21.10% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that VYNE’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of VYNE currently trading nearly -8.56% and -27.82% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.68, while the 7-day volatility ratio is showing 13.44% which for the 30-day chart, stands at 10.76%. Furthermore, VYNE Therapeutics Inc. (VYNE)’s beta value is 1.09, and its average true range (ATR) is 0.05.

Data on historical trading for VYNE Therapeutics Inc. (NASDAQ:VYNE) indicates that the trading volumes over the past 3 months, they’ve averaged 706.13K. According to company’s latest data on outstanding shares, there are 53.55 million shares outstanding.

Nearly 3.10% of VYNE Therapeutics Inc.’s shares belong to company insiders and institutional investors own 25.40% of the company’s shares. The stock has fallen by -60.97% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VYNE stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam